General Information of Drug Combination (ID: DCPOUHM)

Drug Combination Name
Emtricitabine Maraviroc
Indication
Disease Entry Status REF
HIV Infection Phase 1 [1]
Component Drugs Emtricitabine   DMBMUWZ Maraviroc   DMTL94F
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Emtricitabine
Disease Entry ICD 11 Status REF
Hepatitis virus infection 1E50-1E51 Approved [2]
Human immunodeficiency virus infection 1C62 Approved [2]
Hepatitis B virus infection 1E51.0 Phase 3 [3]
Emtricitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [2]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Decreases Expression [6]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Deoxycytidine kinase (DCK) OTW8HLZC DCK_HUMAN Affects Binding [8]
------------------------------------------------------------------------------------
Indication(s) of Maraviroc
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [4]
Chronic obstructive pulmonary disease CA22 Phase 3 [4]
Maraviroc Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Antagonist [9]
CCR5 messenger RNA (CCR5 mRNA) TTJIH8Q CCR5_HUMAN Antagonist [10]
------------------------------------------------------------------------------------
Maraviroc Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01505114) Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Clinical pipeline report, company report or official report of Gilead (2011).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
5 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
6 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
7 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
8 Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. doi: 10.1021/jm0700215. Epub 2007 May 27.
9 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
10 Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
11 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.